SCHEMBL1926410

SCHEMBL1926410

O=c1c(Nc2ccnc(Nc3ccc(I)cc3)n2)c(NC2CCC2)c1=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 18/20 0.52
AURKB Q96GD4 2/20 0.50
AURKA O14965 1/20 0.48
SGK1 O00141 1/20 0.47
PLK4 O00444 1/20 0.47
CHEK1 O14757 1/20 0.47
MAPK13 O15264 1/20 0.47
PDPK1 O15530 1/20 0.47
JAK2 O60674 1/20 0.47
ROCK2 O75116 1/20 0.47
CHEK2 O96017 1/20 0.47
FYN P06241 1/20 0.47
CSF1R P07333 1/20 0.47
MET P08581 1/20 0.47
PIM1 P11309 1/20 0.47
FLT1 P17948 1/20 0.47
FGFR3 P22607 1/20 0.47
MARK3 P27448 1/20 0.47
MAPK1 P28482 1/20 0.47
KDR P35968 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1925675 0.95 PLK1 (0.53) PLK1AURKBSGK1PLK4CHEK1
SCHEMBL1926390 0.87 PLK1 (0.65) PLK1AURKBAURKASGK1PLK4
SCHEMBL23453396 0.79 EPHX1 (0.45) PLK1AURKBROCK2CHEK2PIM1
SCHEMBL1926313 0.78 PLK1 (0.75) PLK1SGK1PLK4CHEK1MAPK13
SCHEMBL1925140 0.78 PLK1 (0.61) PLK1SGK1PLK4CHEK1MAPK13
SCHEMBL1925874 0.77 CCR6 (0.38) PLK1AURKBAURKA
SCHEMBL23453394 0.76 ALDH1A1 (0.45) PLK1AURKBROCK2CHEK2PIM1
SCHEMBL1927980 0.71 PLK1 (0.59) PLK1SGK1PLK4CHEK1MAPK13
SCHEMBL29695718 0.70 AURKA (0.64) AURKBAURKAPLK4CHEK1PDPK1
SCHEMBL1925660 0.69 PLK1 (0.65) PLK1AURKBSGK1PLK4CHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7956185-B2 Cyclobut-3-ene-1,2,-dione inhibitors of polo-like kinases ABBOTT LABORATORIES (US) 2011-06-07 US claimed
US-7956185-B2 Cyclobut-3-ene-1,2,-dione inhibitors of polo-like kinases ABBOTT LABORATORIES (US) 2011-06-07 US disclosed
EP-2021316-A1 INHIBITORS OF POLO-LIKE KINASES Abbott Laboratories (US) 2009-02-11 EP disclosed
US-20080015192-A1 INHIBITORS OF POLO-LIKE KINASES ABBVIE INC. 2008-01-17 US disclosed
WO-2007140233-A1 INHIBITORS OF POLO-LIKE KINASES ABBOTT LABORATORIES (US) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015192-A1 INHIBITORS OF POLO-LIKE KINASES PLK1, PLK2, BUB1B PLK1 1/4885AURKB 8/4885AURKA 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.